MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years.
News
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein.
• UK CFOs focused on business expansion in 2022
• Record* number of CFOs say increasing capital investment is a strong priority for their business in the year ahead
• Overwhelming majority of CFOs expect greater investment in digital technology and workforce skills over the next three years
• Despite rising inflation and the emergence of the Omicron variant, CFO risk appetite has nudged higher
• CFOs expect productivity to grow faster in the next three years, than in the years before the pandemic
Cambridge, UK and Durham, NC, USA, 05 January 2022: PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, today announced a collaboration to study oncology targets currently considered undruggable.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration.
Innovate UK, the National Institute of Health Research (NIHR; i4i programme and AI in Health and Care Award) and the Small Business Research Initiative (SBRI) Healthcare have joined forces to offer specialist support to companies within their portfolios, from across the UK, via their Investment Readiness Programme. The programme will support selected companies to gain additional skills and expertise to get them prepared to find and attract investment.
Leading pharmaceutical and biotech product development consultancy, Boyds, has hired regulatory expert in the pharma, biotech and medical devices sectors, Eamonn McGowran as Associate Director.
Based at Boyds’ Irish operation at Talent Garden Dublin, Eamonn’s appointment marks the beginning of the next phase of growth and expansion in Dublin and Europe for Boyds, which will harness his leading and specialist regulatory experience in medical devices to boost and enhance its comprehensive regulatory advice and services portfolio.
Click here to view the December 2021 edition of Dates for Your Diary.
Cambridge, UK and Brussels, Belgium 16 December 2021:
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures (“Bioqube”), a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products.